|The SIGNIFY trial is testing the hypothesis that treatment with ivabradine*, from 7.5 mg bid to 10 mg bid, reduces mortality and cardiovascular events in patients with stable coronary artery disease (CAD), without clinical heart failure.
19 102 stable CAD patients – 51 countries – 1 139 centers
SIGNIFY results were presented during the ESC Congress 2014, in Barcelona.
Download the SIGNIFY results slide set
Download the SIGNIFY baseline slide set
* Ivabradine’s authorized posology in its indications consists in a starting dose of 5 mg b.i.d (2.5 mg b.i.d, if age > 75 years) and a maintenance dose of 5 mg b.i.d possibly increased to 7.5 mg b.i.d or decreased to 2.5 mg according to therapeutic response.